Semler Scientific Inc (SMLR) - Net Assets
Based on the latest financial reports, Semler Scientific Inc (SMLR) has net assets worth $459.75 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($596.68 Million) and total liabilities ($136.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Semler Scientific Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $459.75 Million |
| % of Total Assets | 77.05% |
| Annual Growth Rate | N/A |
| 5-Year Change | 674.51% |
| 10-Year Change | N/A |
| Growth Volatility | 113.88 |
Semler Scientific Inc - Net Assets Trend (2011–2024)
This chart illustrates how Semler Scientific Inc's net assets have evolved over time, based on quarterly financial data. Also explore Semler Scientific Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Semler Scientific Inc (2011–2024)
The table below shows the annual net assets of Semler Scientific Inc from 2011 to 2024. For live valuation and market cap data, see Semler Scientific Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $230.75 Million | +221.40% |
| 2023-12-31 | $71.80 Million | +28.95% |
| 2022-12-31 | $55.68 Million | +22.24% |
| 2021-12-31 | $45.55 Million | +52.88% |
| 2020-12-31 | $29.79 Million | +127.90% |
| 2019-12-31 | $13.07 Million | +211.56% |
| 2018-12-31 | $4.20 Million | +262.45% |
| 2017-12-31 | $-2.58 Million | +11.51% |
| 2016-12-31 | $-2.92 Million | -172.29% |
| 2015-12-31 | $-1.07 Million | -131.20% |
| 2014-12-31 | $3.44 Million | +1264.75% |
| 2013-12-31 | $-295.00K | +91.75% |
| 2012-12-31 | $-3.58 Million | -662.26% |
| 2011-12-31 | $-469.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Semler Scientific Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10508000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $100.70 Million | 43.64% |
| Common Stock | $9.00K | 0.00% |
| Other Components | $130.04 Million | 56.35% |
| Total Equity | $230.75 Million | 100.00% |
Semler Scientific Inc Competitors by Market Cap
The table below lists competitors of Semler Scientific Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lands’ End Inc
NASDAQ:LE
|
$348.28 Million |
|
CMC Magnetics Corp
TW:2323
|
$348.35 Million |
|
INPAQ Technology Co Ltd
TWO:6284
|
$348.42 Million |
|
Autolus Therapeutics plc
F:6A3A
|
$348.45 Million |
|
ON24 Inc
NYSE:ONTF
|
$348.25 Million |
|
EDREAMS ODIGEO UNS.ADR/10
F:K0I
|
$348.18 Million |
|
Dalmia Bharat Sugar and Industries Limited
NSE:DALMIASUG
|
$347.94 Million |
|
Eugene Inv&Sec
KO:001200
|
$347.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Semler Scientific Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 71,795,000 to 230,750,000, a change of 158,955,000 (221.4%).
- Net income of 40,899,000 contributed positively to equity growth.
- New share issuances of 119,602,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $40.90 Million | +17.72% |
| Share Issuances | $119.60 Million | +51.83% |
| Other Changes | $-1.55 Million | -0.67% |
| Total Change | $- | 221.40% |
Book Value vs Market Value Analysis
This analysis compares Semler Scientific Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-0.17 | $355.43 | x |
| 2012-12-31 | $-1.28 | $355.43 | x |
| 2013-12-31 | $-0.12 | $355.43 | x |
| 2014-12-31 | $0.84 | $355.43 | x |
| 2015-12-31 | $-0.22 | $355.43 | x |
| 2016-12-31 | $-0.57 | $355.43 | x |
| 2017-12-31 | $-0.48 | $355.43 | x |
| 2018-12-31 | $0.55 | $355.43 | x |
| 2019-12-31 | $1.63 | $355.43 | x |
| 2020-12-31 | $3.69 | $355.43 | x |
| 2021-12-31 | $5.60 | $355.43 | x |
| 2022-12-31 | $6.96 | $355.43 | x |
| 2023-12-31 | $9.18 | $355.43 | x |
| 2024-12-31 | $28.92 | $355.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Semler Scientific Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.72%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 72.65%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.04x
- Recent ROE (17.72%) is below the historical average (18.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -593.67% | 0.47x | 0.00x | $-1.83 Million |
| 2012 | 0.00% | -228.61% | 0.81x | 0.00x | $-2.38 Million |
| 2013 | 0.00% | -98.20% | 1.32x | 0.00x | $-2.20 Million |
| 2014 | -131.40% | -124.21% | 0.48x | 2.18x | $-4.86 Million |
| 2015 | 0.00% | -121.43% | 2.27x | 0.00x | $-8.39 Million |
| 2016 | 0.00% | -34.36% | 2.42x | 0.00x | $-2.26 Million |
| 2017 | 0.00% | -12.13% | 2.94x | 0.00x | $-1.25 Million |
| 2018 | 119.49% | 23.33% | 2.78x | 1.84x | $4.59 Million |
| 2019 | 115.38% | 46.03% | 1.79x | 1.40x | $13.78 Million |
| 2020 | 47.01% | 36.28% | 1.11x | 1.16x | $11.03 Million |
| 2021 | 37.81% | 32.48% | 1.05x | 1.11x | $12.67 Million |
| 2022 | 25.73% | 25.27% | 0.90x | 1.13x | $8.76 Million |
| 2023 | 28.67% | 30.19% | 0.87x | 1.09x | $13.40 Million |
| 2024 | 17.72% | 72.65% | 0.23x | 1.04x | $17.82 Million |
Industry Comparison
This section compares Semler Scientific Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Semler Scientific Inc (SMLR) | $459.75 Million | 0.00% | 0.30x | $348.27 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Semler Scientific Inc
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. The company's products serve cardi… Read more